Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06119581 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Study acronym: SUNRAY-01
StatusRecruiting
PhasePhase 3
Started2023-12-21
View on ClinicalTrials.gov ↗
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

Amendment record

Amended 44 times since 2023-11-01; most recent filed 2026-08-21. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-08-21
Amendment Study Status, Contacts/Locations v44
2026-07-17
Amendment Study Status, Contacts/Locations v43
2026-07-03
Amendment Study Status, Contacts/Locations v42
2026-06-17
Amendment Study Status, Contacts/Locations v41
2026-06-02
Amendment Study Status, Contacts/Locations v40
2026-05-18
Amendment Study Status, Contacts/Locations v39
2026-05-11
Amendment Study Status, Contacts/Locations v38
2026-04-17
Amendment Study Status, Contacts/Locations v37
2026-03-20
Amendment Study Status, Contacts/Locations v36
2026-03-10
Amendment Study Status, Study Description, Study Design, Arms and Interventions, Eligibility v35
2026-03-03
Amendment Study Status, Study Design v34
2026-03-02
Amendment Study Status, Study Design, Contacts/Locations v33
2026-01-20
Amendment Study Status, Contacts/Locations v32
2026-01-12
Amendment Study Status, Contacts/Locations v31
2025-12-23
Amendment Study Status, Contacts/Locations v30
2025-12-08
Amendment Study Status, Contacts/Locations v29
2025-11-21
Amendment Study Status, Contacts/Locations v28
2025-11-05
Amendment Study Status, Contacts/Locations v27
2025-10-15
Amendment Study Status, Contacts/Locations v26
2025-10-08
Amendment Study Status, Contacts/Locations v25
2025-09-23
Amendment Study Status, Contacts/Locations v24
2025-09-08
Amendment Study Status, Contacts/Locations v23
2025-08-22
Amendment Study Status, Contacts/Locations v22
2025-07-18
Amendment Study Status, Study Description, Outcome Measures, Eligibility, Contacts/Locations v21
2025-07-07
Amendment Study Status, Contacts/Locations v20
2025-06-25
Amendment Study Status, Contacts/Locations v19
2025-05-20
Amendment Study Status, Contacts/Locations v18
2025-05-03
Amendment Study Status, Conditions v17
2025-04-16
Amendment Study Status, Contacts/Locations v16
2025-02-27
Amendment Study Status, Contacts/Locations v15
2025-01-22
Amendment Study Status, Contacts/Locations v14
2024-11-11
Amendment Study Identification, Study Status, Sponsor/Collaborators, Outcome Measures, Eligibility v13
2024-10-17
Amendment Study Status, Contacts/Locations v12
2024-09-23
Amendment Study Status, Contacts/Locations v11
2024-09-09
Amendment Study Status, Arms and Interventions v10
2024-08-22
Amendment Study Status, Contacts/Locations v9
2024-07-11
Amendment Study Status, Contacts/Locations v8
2024-06-19
Amendment Study Status, Contacts/Locations v7
2024-05-28
Amendment Study Status, Contacts/Locations v6
2024-05-03
Amendment Study Status, Contacts/Locations v5
2024-04-25
Amendment Study Status, Contacts/Locations v4
2024-04-05
Amendment Study Status, Contacts/Locations v3
2024-02-27
Amendment Study Status, Contacts/Locations v2
2024-01-23
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations, References v1
2023-11-01
Original filing
Trial Details
NCT Number NCT06119581
Lead Sponsor Eli Lilly and Company
Conditions Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Enrollment 1,264 participants
Start Date 2023-12-21
Primary Completion 2027-11 (estimated)
Study Completion 2031-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-24